Geriatric Oncology

Top Story

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process
November 16, 2017

WASHINGTON — When diagnosed with Hodgkin lymphoma at the age of 33 years, FDA Commissioner Scott Gottlieb, MD, was told he had a 90% chance of survival.

“Ninety percent doesn’t sound so good if it’s you,” Gottlieb, now 44, told HemOnc Today following a keynote presentation at the Friends of Cancer Research Annual Meeting. “So, to me, that 10% sounded pretty grim.”

In the Journals Plus

Androgen deprivation therapy does not increase risk for Alzheimer’s disease, dementia

November 14, 2017
Older men treated with androgen deprivation therapy for prostate cancer appeared to be at no greater risk for Alzheimer’s disease or dementia, according to a study…
Meeting News

Trabectedin maintains safety, efficacy for older patients with advanced soft tissue sarcoma

November 10, 2017
WAILEA, Hawaii — The safety and efficacy of trabectedin for advanced leiomyosarcoma or liposarcoma appeared comparable among older and younger patients, according…
In the Journals Plus

ASCO: Even light alcohol use increases risk for cancer

November 7, 2017
Alcohol use — whether light, moderate or heavy — increases cancer risk, and public health measures are needed to reduce high-risk alcohol consumption…
More Headlines »
CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Video

Baseball great Mike Schmidt became ‘concerned about dying’ after melanoma diagnosis

September 25, 2017
More »
Resource Centers

CME ABIM MOC

Ace the Case: A 48-Year-Old Female Diagnosed With Polycythemia Vera (PV) 7 Years Ago

There is no commercial support for this activity.

This CME case study will discuss the treatment of polycythemia rubra vera.
More »